Welcome to our dedicated page for Bio-Path Holdings news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Holdings stock.
Bio-Path Holdings Inc. (NASDAQ: BPTH) is a pioneering biotechnology company focused on developing innovative therapeutic products through its proprietary DNAbilize® technology. This technology enables the delivery of nucleic acid drugs throughout the human body via simple intravenous infusion. Bio-Path's primary focus is on oncology, aiming to provide effective treatments for various forms of cancer.
The company's lead product candidate, prexigebersen (BP1001), is currently in Phase II clinical trials for Acute Myeloid Leukemia (AML) in combination with low-dose cytarabine (LDAC) and decitabine. Additionally, Bio-Path is exploring prexigebersen's potential in combination with dasatinib for patients with blast-phase and accelerated-phase Chronic Myeloid Leukemia (CML).
Another key candidate, BP1002, targets the Bcl-2 protein, which plays a crucial role in cell survival for many cancers. BP1002 is being evaluated for its effectiveness against lymphoma and solid tumors, offering hope for venetoclax-resistant AML patients. The company's technological advantage lies in its DNAbilize® platform, a liposomal antisense DNA method that significantly improves oligonucleotide therapeutics' delivery and efficacy.
Bio-Path Holdings continues to expand its pipeline with additional candidates such as BP1003, a STAT3 antisense oligodeoxynucleotide, and BP1001-A, a modification designed for solid tumors. These developments emphasize the company's commitment to addressing unmet medical needs in oncology.
Recently, Bio-Path has made significant strides in its clinical programs, receiving positive feedback from the U.S. FDA and advancing its trials at renowned institutions including Weill Cornell Medical College and The University of Texas MD Anderson Cancer Center. The company maintains a robust intellectual property portfolio to protect its innovative DNAbilize® platform.
For investors and stakeholders, Bio-Path Holdings represents a forward-thinking entity with a strategic focus on developing novel RNAi nanoparticle drugs. The company's advancements in the clinical and preclinical stages underline its potential to make substantial contributions to cancer treatment paradigms.
Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced the successful completion of the safety run-in phase of Stage 2 in its Phase 2 clinical study for prexigebersen (BP1001), targeting acute myeloid leukemia (AML). Six evaluable patients received the triple combination therapy of prexigebersen, decitabine, and venetoclax, with a favorable safety profile and no dose-limiting toxicities. Notably, 83% of patients demonstrated clinical activity. The trial continues enrolling patients, aiming for significant efficacy data to petition the FDA for accelerated approval.
Bio-Path Holdings (NASDAQ: BPTH) announced a virtual poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting from April 10-15 and May 17-21, 2021. Dr. Maria Gagliardi will present pre-clinical studies of BP1002 combined with decitabine, targeting venetoclax-resistant cancer cells.
Presentation Details:
Date: April 10, 2021
Time: 8:30 am ET
Session: Biological Therapeutic Agents
Abstract Number: 939
Title: Efficacy of BP1002 with decitabine in resistant cells.
Bio-Path Holdings (NASDAQ:BPTH) announced its financial results for 2020, reporting a net loss of $10.9 million, or $2.83 per share, compared to a loss of $8.6 million in 2019. Research and development expenses rose to $6.6 million from $4.6 million, reflecting increased clinical activity. The company raised $13 million through a public offering and secured a new U.S. patent for its DNAbilize® platform technology. Bio-Path commenced a Phase 1 trial for BP1002.
Bio-Path Holdings (NASDAQ: BPTH) will host a live conference call on March 10, 2021, at 8:30 a.m. ET to report its financial results for 2020 and provide a business overview. The call can be accessed at (844) 815-4963 domestically or (210) 229-8838 internationally, using conference ID 6296959. Additionally, a live audio webcast will be available on the company's website. Bio-Path focuses on developing its proprietary DNAbilize® technology for targeted nucleic acid cancer treatments. Key products include prexigebersen, in Phase 2 trials for blood cancers, and BP1002, under evaluation for lymphoma.
Bio-Path Holdings, Inc. (Nasdaq:BPTH) has successfully closed its public offering of 1,710,600 shares of common stock at $7.60 each, raising approximately $13.0 million before fees. Proceeds are intended for working capital and general corporate purposes. Roth Capital Partners served as the sole placement agent for the offering. The shares were offered under an effective shelf registration statement, and the company is developing novel cancer treatments utilizing its DNAbilize® technology, targeting specific protein pathways.
Bio-Path Holdings, Inc. (Nasdaq:BPTH) announced a public offering of 1,710,600 shares at $7.60 each, raising approximately $13 million before expenses. The offering is expected to close on February 18, 2021. Proceeds will be utilized for working capital and general corporate purposes. Roth Capital Partners is the sole placement agent for this offering. A registration statement related to the shares has been declared effective by the SEC. Bio-Path is advancing its DNAbilize® technology aimed at developing targeted cancer drugs, including prexigebersen currently in Phase 2 studies.
Bio-Path Holdings (Nasdaq: BPTH) has announced its intention to offer and sell shares of its common stock in a public offering, subject to market conditions. Roth Capital Partners is the sole placement agent for this offering. The net proceeds will be utilized for working capital and corporate purposes. A preliminary prospectus will be filed with the SEC as part of an effective shelf registration statement declared on June 5, 2019. This offering may present investors with new opportunities, although specific terms and timing remain uncertain.
Bio-Path Holdings (NASDAQ:BPTH) announced the granting of U.S. Patent No. 10,898,506, enhancing protection for its DNAbilize technology. This patent covers P-ethoxy nucleic acids for liposomal formulation, strengthening the company's intellectual property. Additionally, a notification for U.S. Patent No. 10,927,379 related to its lead product prexigebersen is set to issue on February 23, 2021. The new patents bolster Bio-Path's competitive edge and safeguard ongoing clinical trials, particularly in treating acute myeloid leukemia.
Bio-Path Holdings (NASDAQ:BPTH) has initiated a Phase 1 clinical trial for BP1002, targeting Bcl-2 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL).
The trial aims to enroll six patients, assessing safety, tolerability, and pharmacokinetics over a four-week treatment period. BP1002 has demonstrated potent inhibition of Bcl-2 in preclinical studies, potentially offering a new therapy for patients resistant to existing treatments like venetoclax. With notable unmet medical needs in this area, Bio-Path anticipates preliminary efficacy results.
Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its Q3 2020 financial results, reporting a net loss of $3.0 million ($0.80 per share), an increase from $2.2 million ($0.78 per share) in Q3 2019. R&D expenses rose to $2.0 million due to Phase 2 trial enrollment for prexigebersen in AML. The company has $12.1 million in cash remaining and raised approximately $4.6 million through a stock offering post-Q3. Significant advancements include the initiation of the first patient in Stage 2 of the Phase 2 trial for AML and a strategic patent allowance for prexigebersen.
FAQ
What is the current stock price of Bio-Path Holdings (BPTH)?
What is the market cap of Bio-Path Holdings (BPTH)?
What is Bio-Path Holdings Inc. known for?
What is DNAbilize® technology?
What is prexigebersen (BP1001)?
What is BP1002 and what does it target?
Which institutions are involved in Bio-Path's clinical trials?
What is the potential advantage of BP1002 over current treatments?
What are the main benefits of DNAbilize® technology for patients?
What is BP1003 and what does it target?
How does Bio-Path Holdings protect its innovations?
How can investors get more information about Bio-Path Holdings?
